应交易所要求,美/港股行情延时15分钟展示,下载APP即可免费查看实时行情。
关闭
CTXR Citius Pharmaceuticals, Inc.
盘前交易 04-18 08:27:23 EDT
0.8162
+0.0664
+8.86%
盘前
0.9222
+0.1060
+12.99%
08:27 EDT
最高
0.8391
最低
0.7451
成交量
86.02万
今开
0.7501
昨收
0.7498
日振幅
12.54%
总市值
1.30亿
流通市值
1.20亿
总股本
1.59亿
成交额
68.90万
换手率
0.59%
流通股本
1.47亿
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
北京优虎网络科技有限公司
资讯
新帖
简况
Citius Pharmaceuticals Inc 报告截至 12 月的季度业绩 - 收益摘要
Reuters · 02-15
Citius Pharmaceuticals Inc 报告截至 12 月的季度业绩 - 收益摘要
Citius Pharmaceuticals Inc 预计每股收益 13 美分 - 财报前瞻
Reuters · 02-06
Citius Pharmaceuticals Inc 预计每股收益 13 美分 - 财报前瞻
Citius 制药公司公布截至 9 月的季度业绩 - 盈利摘要
Reuters · 2023-12-30
Citius 制药公司公布截至 9 月的季度业绩 - 盈利摘要
Citius Pharmaceuticals Inc 预计每股亏损 2 美分 - 财报前瞻
Reuters · 2023-12-18
Citius Pharmaceuticals Inc 预计每股亏损 2 美分 - 财报前瞻
加载更多
公司概况
公司名称:
Citius Pharmaceuticals, Inc.
所属市场:
NASDAQ
上市日期:
--
主营业务:
Citius Pharmaceuticals, Inc.于2007年1月23日成立为马萨诸塞州有限责任公司Citius Pharmaceuticals,LLC。总部位于新泽西州克兰福德的公司是一家致力于重症监护产品开发和商业化的专业制药公司针对重要的医疗需求,重点是辅助癌症护理和独特处方产品中的抗感染产品。他们的目标是通过提供解决未满足的医疗需求的治疗产品来实现领先的市场地位。以前批准的具有重要安全性和有效性数据的药物的新配方是寻求减少与药物开发相关的发展和临床风险的核心焦点。他们的战略以具有知识产权和监管排他性保护的产品为中心,同时提供优于其他现有治疗方法的竞争优势。
发行价格:
--
{"stockData":{"symbol":"CTXR","market":"US","secType":"STK","nameCN":"Citius Pharmaceuticals, Inc.","latestPrice":0.8162,"timestamp":1713384000000,"preClose":0.7498,"halted":0,"volume":860234,"hourTrading":{"tag":"盘前","latestPrice":0.9222,"preClose":0.8162,"latestTime":"08:27 EDT","volume":103725,"amount":98009.706861,"timestamp":1713443234391},"delay":0,"floatShares":146773669,"shares":159094781,"eps":-0.254605,"marketStatus":"盘前交易","marketStatusCode":1,"change":0.0664,"latestTime":"04-18 08:27:23 EDT","open":0.7501,"high":0.8391,"low":0.7451,"amount":689006.4008382,"amplitude":0.125367,"askPrice":0.9637,"askSize":1,"bidPrice":0.905,"bidSize":10,"shortable":3,"etf":0,"ttmEps":-0.254605,"exchange":"NASDAQ","tradingStatus":1,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1713447000000},"adr":0,"adjPreClose":0.8162,"adrRate":0,"preHourTrading":{"tag":"盘前","latestPrice":0.9222,"preClose":0.8162,"latestTime":"08:27 EDT","volume":103725,"amount":98009.706861,"timestamp":1713443234391},"postHourTrading":{"tag":"盘后","latestPrice":0.99,"preClose":0.8162,"latestTime":"19:59 EDT","volume":183117,"amount":171482.5053,"timestamp":1713398399074},"volumeRatio":1.2149552617962203},"requestUrl":"/m/hq/s/CTXR","defaultTab":"news","newsList":[{"id":"2411564115","title":"Citius Pharmaceuticals Inc 报告截至 12 月的季度业绩 - 收益摘要","url":"https://stock-news.laohu8.com/highlight/detail?id=2411564115","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2411564115?lang=zh_cn&edition=full","pubTime":"2024-02-15 07:57","pubTimestamp":1707955072,"startTime":"0","endTime":"0","summary":" * Citius Pharmaceuticals Inc 报告了截至12月底的季度调整后每股亏损6美分。* 报告收入为零,分析师预期为 2130 万美元。* Citius Pharmaceuticals Inc 报告的本季度每股收益为亏损 6 美分。* 该公司当季亏损 923 万美元。* Citius Pharmaceuticals Inc 本季度股价下跌了 10.1%。2月14日 - 预测变化 * 在过去的 30 天里,没有覆盖该公司的分析师对盈利预期进行修正。华尔街对 Citius Pharmaceuticals Inc 的 12 个月目标价中位数为 4.00 美元。本摘要由 LSEG 2 月 14 日 11:57 p.m. UTC 数据机器生成。(如对本报告中的数据有任何疑问,请联系 Estimates.Support@lseg.com。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2409473556","title":"Citius Pharmaceuticals Inc 预计每股收益 13 美分 - 财报前瞻","url":"https://stock-news.laohu8.com/highlight/detail?id=2409473556","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2409473556?lang=zh_cn&edition=full","pubTime":"2024-02-06 19:04","pubTimestamp":1707217490,"startTime":"0","endTime":"0","summary":" * Citius Pharmaceuticals Inc 预计将于2月8日公布截至2023年12月31日的财报(,预计)。* LSEG 分析师对 Citius Pharmaceuticals Inc 的平均预期为每股收益 13 美分。* 华尔街对 Citius Pharmaceuticals Inc 的 12 个月目标价中位数为 4.00 美元,高于上一次 0.60 美元的收盘价。2月6日 - 本摘要于北京时间 2 月 6 日 11:04 机器生成。除非另有说明,否则所有数据均以美元为单位。(如对本报告中的数据有任何疑问,请联系 Estimates.Support@lseg.com。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2395051562","title":"Citius 制药公司公布截至 9 月的季度业绩 - 盈利摘要","url":"https://stock-news.laohu8.com/highlight/detail?id=2395051562","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2395051562?lang=zh_cn&edition=full","pubTime":"2023-12-30 07:27","pubTimestamp":1703892461,"startTime":"0","endTime":"0","summary":"* Citius Pharmaceuticals Inc 报告,截至9月底的季度调整后每股亏损8美分,低于去年同期的每股收益-5美分。两位分析师对该季度的平均预期是每股亏损 2 美分。* Citius Pharmaceuticals Inc 报告的本季度每股收益为亏损 7 美分。* 该公司当季亏损 1110 万美元。* Citius Pharmaceuticals Inc 的股价本季度上涨了 12.8%,今年迄今为止下跌了 2.3%。* 在过去 30 天内,没有覆盖该公司的分析师对盈利预期进行修正。华尔街对 Citius Pharmaceuticals Inc 的 12 个月目标价中位数为 4.00 美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2392961376","title":"Citius Pharmaceuticals Inc 预计每股亏损 2 美分 - 财报前瞻","url":"https://stock-news.laohu8.com/highlight/detail?id=2392961376","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2392961376?lang=zh_cn&edition=full","pubTime":"2023-12-18 19:03","pubTimestamp":1702897388,"startTime":"0","endTime":"0","summary":"* Citius Pharmaceuticals Inc 预计在12月20日公布截至2023年6月30日的业绩时,季度收入将没有变化(预计)。* * LSEG分析师对Citius Pharmaceuticals Inc的平均预期是每股亏损2美分。* 华尔街对 Citius Pharmaceuticals Inc 的 12 个月目标价中位数为 4.00 美元,高于上一次收盘价 0.80 美元。12月18日 - 本摘要于北京时间 12 月 18 日 11:02 机器生成。除非另有说明,否则所有数据均以美元为单位。(如对本报告中的数据有任何疑问,请联系 Estimates.Support@lseg.com。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.citiuspharma.com","stockEarnings":[{"period":"1week","weight":-0.04},{"period":"1month","weight":0.1333},{"period":"3month","weight":0.0883},{"period":"6month","weight":0.1741},{"period":"1year","weight":-0.5053},{"period":"ytd","weight":0.0789}],"compareEarnings":[{"period":"1week","weight":-0.0264},{"period":"1month","weight":-0.024},{"period":"3month","weight":0.0505},{"period":"6month","weight":0.1884},{"period":"1year","weight":0.2084},{"period":"ytd","weight":0.0531}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Citius Pharmaceuticals, Inc.于2007年1月23日成立为马萨诸塞州有限责任公司Citius Pharmaceuticals,LLC。总部位于新泽西州克兰福德的公司是一家致力于重症监护产品开发和商业化的专业制药公司针对重要的医疗需求,重点是辅助癌症护理和独特处方产品中的抗感染产品。他们的目标是通过提供解决未满足的医疗需求的治疗产品来实现领先的市场地位。以前批准的具有重要安全性和有效性数据的药物的新配方是寻求减少与药物开发相关的发展和临床风险的核心焦点。他们的战略以具有知识产权和监管排他性保护的产品为中心,同时提供优于其他现有治疗方法的竞争优势。","yearOnYearQuotes":[{"month":1,"riseRate":0.571429,"avgChangeRate":0.137229},{"month":2,"riseRate":0.571429,"avgChangeRate":0.062077},{"month":3,"riseRate":0.571429,"avgChangeRate":0.018089},{"month":4,"riseRate":0.428571,"avgChangeRate":0.003242},{"month":5,"riseRate":0.5,"avgChangeRate":-0.015406},{"month":6,"riseRate":0.5,"avgChangeRate":0.08938},{"month":7,"riseRate":0.5,"avgChangeRate":-0.009929},{"month":8,"riseRate":0.333333,"avgChangeRate":-0.069949},{"month":9,"riseRate":0.285714,"avgChangeRate":-0.069207},{"month":10,"riseRate":0.285714,"avgChangeRate":-0.072055},{"month":11,"riseRate":0.571429,"avgChangeRate":0.029814},{"month":12,"riseRate":0.142857,"avgChangeRate":0.059334}],"exchange":"NASDAQ","name":"Citius Pharmaceuticals, Inc.","nameEN":"Citius Pharmaceuticals, Inc."},"APP":{"userAgent":"claudebot","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Citius Pharmaceuticals, Inc.(CTXR)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Citius Pharmaceuticals, Inc.(CTXR)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Citius Pharmaceuticals, Inc.,CTXR,Citius Pharmaceuticals, Inc.股票,Citius Pharmaceuticals, Inc.股票老虎,Citius Pharmaceuticals, Inc.股票老虎国际,Citius Pharmaceuticals, Inc.行情,Citius Pharmaceuticals, Inc.股票行情,Citius Pharmaceuticals, Inc.股价,Citius Pharmaceuticals, Inc.股市,Citius Pharmaceuticals, Inc.股票价格,Citius Pharmaceuticals, Inc.股票交易,Citius Pharmaceuticals, Inc.股票购买,Citius Pharmaceuticals, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Citius Pharmaceuticals, Inc.(CTXR)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Citius Pharmaceuticals, Inc.(CTXR)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}